电针干预过氧化物酶体增殖物激活受体-γ通路增加自噬改善神经根型颈椎病疼痛的模型研究

Model study on improvement of cervical spondylotic radiculopathy pain by increasing autophagy through electroacupuncture intervention in peroxisome proliferator-activated receptor-γ pathway

  • 摘要:
    目的 探讨电针(EA)干预过氧化物酶体增殖物激活受体-γ(PPAR-γ)通路改善神经根型颈椎病(CSR)疼痛的机制及与自噬的关系。
    方法 将大鼠分为假手术组(Sham组)、CSR组、电针组(EA组)、EA+GW9622(PPAR-γ拮抗剂)组、EA+吡格列酮组。干预10、20、30 d后,检测各组大鼠神经痛阈值,并采用苏木精-伊红(HE)染色观察脊髓组织神经元细胞受损情况, TUNEL检测细胞凋亡情况,酶联免疫吸附实验检测白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、前列腺素E2(PEG2)和β-内啡肽(β-EP)水平,蛋白免疫印迹检测自噬相关蛋白PPAR-γ、微管相关蛋白1轻链3Ⅱ型(LC3 Ⅱ)、Beclin-1蛋白表达。
    结果 与Sham组相比, CSR组大鼠神经痛阈值、β-EP、PPAR-γ、LC3 Ⅱ、Beclin-1表达水平降低,细胞凋亡率、IL-1β、IL-6、TNF-α以及PEG2水平增高; 与CSR组相比, EA组、EA+GW9622组、EA+吡格列酮组大鼠神经痛阈值、β-EP、PPAR-γ、LC3 Ⅱ、Beclin-1表达水平增加,细胞凋亡率、IL-1β、IL-6、TNF-α以及PEG2降低; EA+GW9622组大鼠神经痛阈值、β-EP、PPAR-γ、LC3 Ⅱ、Beclin-1表达水平低于EA组,细胞凋亡率、IL-1β、IL-6、TNF-α以及PEG2高于EA组; EA+吡格列酮组大鼠神经痛阈值、β-EP、PPAR-γ、LC3 Ⅱ、Beclin-1表达水平高于EA组,细胞凋亡率、IL-1β、IL-6、TNF-α以及PEG2低于EA组; 上述组间差异均有统计学意义(P < 0.05)。
    结论 EA通过激活PPAR-γ通路介导的自噬来抑制脊髓组织病理损伤和细胞凋亡,减轻脊髓神经炎症反应,改善CSR模型的疼痛症状。

     

    Abstract:
    Objective To investigate the mechanism of electroacupuncture (EA) intervention in the peroxisome proliferator-activated receptor-γ (PPAR-γ) pathway for improving pain in cervicalspondylotic radiculopathy (CSR) and its relationship with autophagy.
    Methods Rats were divided into sham-operated group (Sham group), CSR group, EA group, EA+GW9662 (PPAR-γ antagonist) group, and EA+pioglitazone group. After 10, 20 and 30 days of intervention, the neuralgia threshold of the rats in each group was measured; the hematoxylin and eosin (HE) staining was used to observe the damage to neuronal cells in the spinal cord tissue, TUNEL was used to detect cell apoptosis, the enzyme-linked immunosorbent assay (ELISA) wasused to detect the levels of interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), prostaglandin E2 (PGE2) and β-endorphin (β-EP), and the Western blot analysis was used to detect the expression of autophagy-related proteins such as PPAR-γ, microtubule-associated protein 1 light chain 3 type Ⅱ (LC3 Ⅱ), and Beclin-1.
    Results Compared with the Sham group, the CSR group showed decreased neuralgia thresholds, β-EP, PPAR-γ, LC3 Ⅱ and Beclin-1 expression levels, as well as increased cell apoptosis rate and IL-1β, IL-6, TNF-α and PGE2 levels; compared with the CSR group, the EA group, EA+GW9662 group, and EA+pioglitazone group showed increased neuralgia thresholds, β-EP, PPAR-γ, LC3 Ⅱ and Beclin-1 expression levels as well as decreased cell apoptosis rates and IL-1β, IL-6, TNF-αand PGE2 levels; the neuralgia thresholds, β-EP, PPAR-γ, LC3 Ⅱ, and Beclin-1 expression levels in the EA+GW9662 group were lower than those in the EA group, while the cell apoptosis rate and IL-1β, IL-6, TNF-α and PGE2 levels were higher; in contrast, the neuralgia thresholds, β-EP, PPAR-γ, LC3 Ⅱ and Beclin-1 expression levels in the EA+pioglitazone group were higher than those in the EA group, with lower cell apoptosis rates and IL-1β, IL-6, TNF-α and PGE2 levels; the differences mentioned above were statistically significant between the different groups (P < 0.05).
    Conclusion EA inhibits pathological damage and cell apoptosis in spinal cord tissue, reduces spinal cord neuroinflammatory responses, and improves pain symptoms in CSR models by activating autophagy mediated by the PPAR-γ pathway.

     

/

返回文章
返回